The Evolving Role of Chromatography in Model-Based Analytical Science

Pharmaceutical development is moving toward faster, more dependable analytical strategies that streamline development, cut costs, reduce waste, and lessen environmental impact across both research and commercial testing. The broader vision is a highly automated, data-driven manufacturing environment where real-time monitoring reduces reliance on traditional end-product quality testing. AI, automation, digital tools, and predictive modeling are helping shift analytical science away from trial-and-error experimentation by improving accuracy while lowering material and solvent consumption. Examples include replacing some ultrahigh performance liquid chromatography (UHPLC) methods with near-infrared spectroscopy (NIR), adopting alternatives to animal-based microbiological testing, and using predictive models to estimate drug dissolution without extensive laboratory studies. Collectively, these advances are reshaping analytical laboratories by speeding development, improving sustainability, and preserving the scientific rigor needed for regulatory compliance.

As NIR and chemometric models rely heavily on chromatographic reference data, Koen Vanhoutte of Johnson & Johnson Innovative Medicine discusses the implications for the future role and expectations of chromatography in analytical science.

View Additional Commentary by Koen Vanhoutte:
Beyond Trial-and-Error: Self-Optimizing LC Workflows

Koen Vanhoutte is an Executive Director in pharmaceutical research and development with more than 25 years of industrial experience in analytical chemistry. He holds a Ph.D. in chemistry from the University of Antwerp, with his early scientific training and core expertise rooted in liquid chromatography–mass spectrometry (LC‑MS) and chromatographic method development. Over the course of his career, he has built extensive experience in Chemistry, Manufacturing and Controls (CMC) across both early‑ and late‑stage pharmaceutical development. He currently leads the Synthetics Analytical Development organization within Johnson & Johnson Innovative Medicine, where he is responsible for defining and delivering analytical strategies across the full product lifecycle, from development through commercial manufacture. His scope includes method development, validation, technology transfer, clinical trial material release, and ICH stability testing for synthetic therapeutics. His involvement in biologics is focused specifically on microbiology‑based analytical methods, and he has extensive experience supporting global regulatory submissions and inspections, including interactions with FDA and EMA. Dr. Vanhoutte is passionate about leading and developing global teams and fostering scientific excellence through people development. He is strongly committed to applying rigorous analytical science to advance therapeutic development, while staying closely connected to evolving analytical methodologies through pragmatic, applied innovation.